• Event Type: Q4 & FY26 Earnings Conference Call held on Wednesday, 20th May, 2026 at 12:00 Hrs IST. The event duration was 65 minutes 09 seconds.
  • Management Participants:
  • Dr. Anwar Daud (Chairman and Managing Director)
  • Mr. Zulfiquar Kamal (Director Finance)
  • Dr. Chandrashekhar Mainde (Technical Director)
  • Mr. Shyam Mohan Patro (Chief Financial Officer)
  • Mr. Zain Daud (Investor Relations)
  • Ms. Deepika Sharma (Go India Advisors)
  • Purpose: Discussion of Q4 and full year FY26 financial results, business outlook, and regulatory update regarding EU GMP compliance and remediation process.
  • Regulatory Update: The company's manufacturing facility at B-21/22 MIDC Area, Kalmeshwar, District Nagpur underwent a regulatory re-inspection by German and Portuguese authorities from 4th May to 7th May 2026 as part of EU GMP compliance. Management expects a positive outcome pending final inspection report and CAPA resolution.
  • Financial Period Discussed: Q4 FY26 and full year FY26 ended March 31, 2026.
  • Forward-looking Statements: Management expressed optimism for FY27, expecting stronger performance subject to EU GMP reinstatement and geopolitical stability. Projected NIP and OTF business to reach 50% of total revenue with EBITDA margins in the "upper teens" once regulated market commercialization begins.
  • Presentation Availability: The earnings presentation was referenced as available on stock exchanges. The transcript itself is available on the company website at: https://drive.google.com/file/d/1qNUeb7dYdU2P1x91M4wlra7DeZJkVZYT/view
  • Compliance Language: The discussion included forward-looking statements with associated risks. No specific statement about unpublished price sensitive information was made in the transcript.

Additional Notes Section

  • Financial Highlights (Q4 FY26):
  • Total operating income: INR 1,053 million
  • EBITDA: INR 134 million (12.7% margin)
  • PAT: INR 37 million
  • Exports contribution: 82% of operating income
  • NIP and OTF revenue: INR 254 million (22% of operating income)
  • Financial Highlights (FY26):
  • Total operating income: INR 3,744 million (broadly in line with FY25)
  • EBITDA: INR 414 million
  • PAT: INR 58 million
  • R&D investment: INR 311 million allocated to BE studies and registrations
  • Estimated MENA region revenue impact: INR 20-25 crore due to geopolitical disruption
  • Business Updates:
  • CAPA implementation substantially completed
  • International business development function fully staffed under Mr. Vikrant Bendre
  • Three senior leadership appointments made during the year
  • Alternate certification and site transfer activities implemented for business continuity
  • 17 products in NIP and OTF pipeline expected to commercialize within 24 months
  • Dabigatran capsules received MA in May 2026 with European market size of $400 million
  • No financial data was disclosed beyond what was presented in the earnings call.